Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 1/20 | 0.52 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.52 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 7/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.34 |
| ▸ | AKT1 | P31749 | 4/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11026964 | 0.91 | PRKAG1 (0.60) | PRKAG1PRKAA1PRKAB1MDM2TP53 | |
| SCHEMBL11940916 | 0.83 | PRKAG1 (0.45) | PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL11026442 | 0.82 | PRKAG1 (0.52) | PRKAG1PRKAA1PRKAB1IDO1TDO2 | |
| SCHEMBL11025262 | 0.82 | PRKAG1 (0.69) | PRKAG1PRKAA1PRKAB1MGLLIDO1 | |
| SCHEMBL11026040 | 0.80 | PRKAG1 (0.44) | PRKAG1PRKAA1PRKAB1MDM2TP53 | |
| SCHEMBL45587 | 0.77 | PRKAG1 (0.57) | PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL11024274 | 0.77 | PRKAG1 (0.47) | PRKAG1PRKAA1PRKAB1MDM2BACE1 | |
| SCHEMBL11024427 | 0.75 | PRKAG1 (0.50) | PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL11025519 | 0.73 | PRKAG1 (0.81) | PRKAG1PRKAA1PRKAB1MGLLIDO1 | |
| SCHEMBL11026441 | 0.69 | PRKAG1 (0.48) | PRKAG1PRKAA1PRKAB1MDM2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809369-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | claimed |
| EP-2668165-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-04 | — | — | EP | claimed |
| WO-2012101068-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | claimed |
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | US | claimed |
| US-8809369-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2668165-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012101068-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | RAB1A, RABL3, RAB7A | PRKAG1 2822/4885PRKAA1 2934/4885PRKAB1 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.